Different initiatives across Europe to enhance losartan utilisation post generics: Impact and implications

Frontiers in Pharmacology

Volumn 5, Issue SEP, 2014, Pages

  Moon, J C ^a   Godman, B ^b,c,d   Petzold, M ^e   Alvarez Madrazo, S ^c   Bennett, K ^f   Bishop, I ^g   Bucsics, A ^h,i   Hesse, U ^j   Martin, A ^k   Simoens, S ^l   Zara, C ^m   Malmstrom R E ^b  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f ST JAMES S HOSPITAL   (Ireland)

^g INFORMATION SERVICES DIVISION   (United Kingdom)

^h UNIVERSITY OF VIENNA   (Austria)

ⁱ Hauptverband der österreichischen Sozialversicherungsträger   (Australia)

^j National Institute for Health Data and Disease Control   (Denmark)

^k NHS Greater Manchester Commissioning Support Unit   (United Kingdom)

^l UNIVERSITY OF LEUVEN   (Belgium)

^m C Agy Hlth Technol Assess Res   (Spain)

more..

Author keywords

Cross national study; Demand side measures; Europe; Generics; Losartan

Indexed keywords

GENERIC DRUG; LOSARTAN;

ARTICLE; AUSTRIA; BELGIUM; DENMARK; DRUG APPROVAL; DRUG COST; DRUG UTILIZATION; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; PRESCRIPTION; RETROSPECTIVE STUDY; SWEDEN; UNITED KINGDOM;

EID: 84907924559     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00219     Document Type: Article

References (56)

1. Frank RG. The ongoing regulation of generic drugs. The New England journal of medicine. 2007;357(20):1993-6.
2. Jack A. Balancing Big Pharma's books. BMJ (Clinical research ed). 2008;336(7641):418-9.
3. Godman B WM, van Woerkom M, Fraeyman J, Alvarez-Madrazo S, Berg C et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Frontiers in Pharmacology Focused Review 2014;5 (Article 106):1-9.
4. Voncina L, Strizrep T, Godman B, Bennie M, Bishop I, Campbell S, et al. Influence of demandside measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert review of pharmacoeconomics & outcomes research. 2011;11(4):469-79.
5. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Policies to enhance prescribing efficiency in europe: findings and future implications. Frontiers in pharmacology. 2010;1:141.
6. Informatics. IIfH. The Global Use of Medicines: Outlook through 2015 http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS%20Institute%20for%20 Healthcare%20Informatics/Global_Use_of_Medicines_Report.pdf May 2011.
7. Moon JC, Flett AS, Godman BB, Grosso AM, Wierzbicki AS. Getting better value from the NHS drug budget. BMJ (Clinical research ed). 2010;341:c6449.
8. Godman B, Wettermark B, Miranda J, Bennie M, Martin A, Malmstrom RE. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries. International journal of clinical practice. 2013;67(9):853-62.
9. Simoens S DBK, Miranda J, Bennie M, Malmström RE, Godman B. Measures to enhance ARB prescribing efficiency in Belgium following generic losartan: impact and implications for the future. Journal of Pharmaceutical Health Services Research 2013;4:173-81.
10. Bucsics A, Godman B, Burkhardt T, Schmitzer M, Malmstrom RE. Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries. Expert review of pharmacoeconomics & outcomes research. 2012;12(6):809-19.
11. Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. The Cochrane database of systematic reviews. 2008(4):Cd003822.
12. Svanstrom H, Pasternak B, Hviid A. Association of treatment with losartan vs candesartan and mortality among patients with heart failure. JAMA: the journal of the American Medical Association. 2012;307(14):1506-12.
13. Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. International journal of clinical practice. 2008;62(3):480-4.
14. Makani H, Bangalore S, Supariwala A, Romero J, Argulian E, Messerli FH. Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis. European heart journal. 2014;35(26):1732-42.
15. Hesse U, Godman B, Petzold M, Martin A, Malmstrom RE. Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries. Applied health economics and health policy. 2013;11(6):677-85.
16. Martin A, Godman B, Miranda J, Tilstone J, Saleem N, Olsson E, et al. Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications. Journal of comparative effectiveness research. 2014;3(1):41-51.
17. Godman B BM, Bucsics A et al. Variable approaches in Europe to the availability of generic losartan; implications for the future. Clinical therapeutics. 2013;35(8S):e36-7.
18. Bennie M, Bishop I, Godman B, Campbell S, Miranda J, Finlayson AE, et al. Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland? Quality in primary care. 2013;21(1):7-15.
19. Markovic-Pekovic V, Skrbic R, Godman B, Gustafsson LL. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. Expert review of pharmacoeconomics & outcomes research. 2012;12(5):661-71.
20. Kalaba M, Godman B, Vuksanovic A, Bennie M, Malmstrom RE. Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history? Journal of comparative effectiveness research. 2012;1(6):539-49.
21. Vlahovic-Palcevski V, Gantumur M, Radosevic N, Palcevski G, Vander Stichele R. Coping with changes in the Defined Daily Dose in a longitudinal drug consumption database. Pharmacy world & science: PWS. 2010;32(2):125-9.
22. Ronning M, Blix HS, Harbo BT, Strom H. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose--are drug utilisation data comparable? European journal of clinical pharmacology. 2000;56(9-10):723-7.
23. (WHO) WHO. Introduction to Drug Utilisation Research. WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. ISBN 92 4156234 X (NLM classification: WB 330) http://www.who.int/medicines/areas/quality_safety/safety_efficacy/Drug%20utilization%20researc h.pdf2003.
24. Methodology WCCfDS. ATC/DDD index 2011. WHO, Oslo. 2013:http://www.whocc.no/atc_ddd_index/.
25. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. Journal of clinical pharmacy and therapeutics. 2002;27(4):299-309.
26. McDowall D MR, Meidinger EE, Hay RA Interrupted time series analysis. Sage University Papers Series on Quantitative Applications in the Social Sciences, 07-021 Thousand Oakes, CA: Sage Publications Inc. 1980.
27. Ross-Degnan D, Soumerai SB, Fortess EE, Gurwitz JH. Examining product risk in context. Market withdrawal of zomepirac as a case study. JAMA: the journal of the American Medical Association. 1993;270(16):1937-42.
28. Durbin J WG. Testing for serial correlation in least square regression. Biometrika 1951;37:409-28.
29. Brennan P, Croft P. Interpreting the results of observational research: chance is not such a fine thing. BMJ (Clinical research ed). 1994;309(6956):727-30.
30. Team RDC. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0 http://www. R-project.org/2012.
31. (NHS) RDaTC. Fixed-dose combinations (Part 2) -Use in specific medical conditions: http://www.formulary.cht.nhs.uk/pdf, _doc_files_etc/RDTC/Drug_Updates/062_Fixed- Dose_Combinations_(2).pdf 2008.
32. Godman B, Wettermark B, Hoffmann M, Andersson K, Haycox A, Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert review of pharmacoeconomics & outcomes research. 2009;9(1):65-83.
33. Abuelkhair M, Abdu S, Godman B, Fahmy S, Malmstrom RE, Gustafsson LL. Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi. Expert review of pharmacoeconomics & outcomes research. 2012;12(1):115-24.
34. Simoens S. A reviewof genericmedicine pricing in Europe. GaBI. 2012;1(1):8-12.
35. vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries-an overview. Biosimilars Initiative Journal (GaBI Journal). 2012;1(2):93-100.
36. Godman B, Bishop I, Finlayson AE, Campbell S, Kwon HY, Bennie M. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert review of pharmacoeconomics & outcomes research. 2013;13(4):469-82.
37. Godman B AM, Vitry A, Abdu S, Bennie M, Bishop I et al. Payers endorse generics to enhance prescribing efficiency; impact and future implications, a case history approach. GaBI. 2012;1(2):21-35.
38. Cacace M, Ettelt S, Mays N, Nolte E. Assessing quality in cross-country comparisons of health systems and policies: towards a set of generic quality criteria. Health policy (Amsterdam, Netherlands). 2013;112(1-2):156-62.
39. Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp FM. Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences. Applied health economics and health policy. 2009;7(3):137-47.
40. Gustafsson LL, Wettermark B, Godman B, Andersen-Karlsson E, Bergman U, Hasselstrom J, et al. The 'wise list'- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic & clinical pharmacology & toxicology. 2011;108(4):224-33.
41. Wettermark B, Godman B, Neovius M, Hedberg N, Mellgren TO, Kahan T. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health policy (Amsterdam, Netherlands). 2010;94(3):221-9.
42. Garuoliene K, Godman B, Gulbinovic J, Wettermark B, Haycox A. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert review of pharmacoeconomics & outcomes research. 2011;11(3):343-9.
43. Coma A, Zara C, Godman B, Agusti A, Diogene E, Wettermark B, et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. Expert review of pharmacoeconomics & outcomes research. 2009;9(6):569-81.
44. Godman B, Bucsics A, Burkhardt T, Haycox A, Seyfried H, Wieninger P. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Expert review of pharmacoeconomics & outcomes research. 2008;8(4):357-71.
45. Godman B CS, Suh HS, Finlayson A, Bennie M, Gustafsson L. Ongoing measures to enhance prescribing efficiency across Europe: implications for other countries. J Health Tech Assess 2013;1:27-42.
46. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert review of pharmacoeconomics & outcomes research. 2010;10(6):707-22.
47. Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ (Clinical research ed). 1998;317(7156):465-8.
48. Barton S. Using clinical evidence. BMJ (Clinical research ed). 2001;322(7285):503-4.
49. Olsson E, Kalvemark Sporrong S. Pharmacists' experiences and attitudes regarding generic drugs and generic substitution: two sides of the coin. The International journal of pharmacy practice. 2012;20(6):377-83.
50. Olsson E, Ingman P, Ahmed B, Kalvemark Sporrong S. Pharmacist-patient communication in Swedish community pharmacies. Research in social & administrative pharmacy: RSAP. 2014;10(1):149-55.
51. McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert review of pharmacoeconomics & outcomes research. 2010;10(1):73-85.
52. Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert review of pharmacoeconomics & outcomes research. 2012;12(1):125-30.
53. Andersson K, Sonesson C, Petzold M, Carlsten A, Lonnroth K. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiology and drug safety. 2005;14(5):341-8.
54. Godman B BM, Baumgärtel C, Sovic Brkicic L et al. Essential to increase the use of generics in Europe to maintain comprehensive healthcare? Farmeconomia: Health Economics and Therapeutic Pathways 2012;13 (Suppl 3):5-20.
55. Godman B, De Bruyn K, Miranda J, Raschi E, Bennie M, Barbui C, et al. Generic atypical antipsychotic drugs in Belgium: their influence and implications. Journal of comparative effectiveness research. 2013;2(6):551-61.
56. Cahir C, Fahey T, Tilson L, Teljeur C, Bennett K. Proton pump inhibitors: potential cost reductions by applying prescribing guidelines. BMC health services research. 2012;12:408.